DMKPQ Документы SEC - DMK Pharmaceuticals Corporation- Годовой отчет, доверенное заявление, проспект эмиссии

Основная статистика

LEI	549300EBMD9JZ2H87I37
CIK	887247

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to DMK Pharmaceuticals Corporation

SEC Filings (Chronological Order)

На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.

July 1, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 16, 2024 DMK PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commission
February 7, 2024	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 6, 2024 DMK PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commiss
February 6, 2024	SC 13G/A	US00547W3079 / ADAMIS PHARMACEUTICALS CORP / INTRACOASTAL CAPITAL, LLC - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* DMK Pharmaceuticals Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00547W307 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi
February 5, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 2, 2024 DMK PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 2, 2024 DMK PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commiss
February 5, 2024	EX-99.1	DMK PHARMACEUTICALS CORPORATION 8-K DMK PHARMACEUTICALS CORPORATION 8-K EXHIBIT 99.1 DMK Pharmaceuticals Commences Restructuring Proceeding SAN DIEGO, Feb. 2, 2024 (GLOBE NEWSWIRE) - DMK Pharmaceuticals Corporation (Nasdaq: DMK) (“DMK” or the “Company”), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, and certain o
January 31, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 25, 2024 DMK PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commiss
January 23, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 22, 2024 DMK PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 22, 2024 DMK PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commiss
January 23, 2024	EX-3.1	AMENDED AND RESTATED BYLAWS OF DMK PHARMACEUTICALS CORPORATION ARTICLE I OFFICES DMK Pharmaceuticals Corporation 8-K Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF DMK PHARMACEUTICALS CORPORATION ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at su
January 23, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
January 3, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 3, 2024 DMK PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 3, 2024 DMK PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commissi
January 3, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 28, 2023 DMK PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 28, 2023 DMK PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commis
January 3, 2024	EX-99.1	DMK Pharmaceuticals Corporation 8-K DMK Pharmaceuticals Corporation 8-K Exhibit 99.1 DMK Pharmaceuticals Corporation Focused on reducing deaths and addiction January 2024 2 3 Dr. Versi appointed CEO in May 2023 • Large (Lilly, Pfizer, Astellas) and small companies (Odyssey, Plethora, Auxilium, Mt. Cook) • Medical lead at Pfizer – team that created the overactive bladder market o Current OAB market >$5B • Planned and executed clinica
January 3, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
December 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 15, 2023 DMK PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 15, 2023 DMK PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Co
December 21, 2023	EX-99.1	DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI Company seeking commercialization partnerships in the United States, Canada, and Europe to expand revenue generation DMK Pharmaceuticals Corporation 8-K Exhibit 99.1 DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI Company seeking commercialization partnerships in the United States, Canada, and Europe to expand revenue generation SAN DIEGO, Dec. 21, 2023 (GLOBE NEWSWIRE) - DMK Pharmaceuticals Corporation (Nasdaq: DMK) (“DMK”), a commercial stage neuro-biotech company primarily focused on developing
December 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 30, 2023 DMK PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 30, 2023 DMK PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commis
December 4, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
November 28, 2023	EX-99.1	DMK Pharmaceuticals Corporation 8-K DMK Pharmaceuticals Corporation 8-K Exhibit 99.1 DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update Now seeking out license opportunities for SYMJEPI® Your publication date and time will appear here. \| Source: DMK Pharmaceuticals Corporation SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) - DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial stag
November 28, 2023	8-K	Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 21, 2023 DMK PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Co
November 15, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
November 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 9, 2023 DMK PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 9, 2023 DMK PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commiss
November 15, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
November 15, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commi
November 14, 2023	EX-4.1	COMMON STOCK PURCHASE WARRANT ADAMIS PHARMACEUTICALS CORPORATION DMK Pharmaceuticals Corporation 10-Q Exhibit 4.1 COMMON STOCK PURCHASE WARRANT ADAMIS PHARMACEUTICALS CORPORATION Warrant Shares: 5,930,000 Issue Date: August 4, 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Cede & Co., a nominee of The Depository Trust Company or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on
November 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 14, 2023 DMK PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 14, 2023 DMK PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commis
November 14, 2023	EX-4.3	ADAMIS PHARMACEUTICALS CORPORATION EQUINITI TRUST COMPANY, LLC, as Warrant Agent Warrant Agency Agreement Dated as of August 4, 2023 WARRANT AGENCY AGREEMENT DMK Pharmaceuticals Corporation 10-Q Exhibit 4.3 ADAMIS PHARMACEUTICALS CORPORATION and EQUINITI TRUST COMPANY, LLC, as Warrant Agent Warrant Agency Agreement Dated as of August 4, 2023 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of August 4, 2023 (“Agreement”), between Adamis Pharmaceuticals Corporation, a corporation organized under the laws of the State of Delaware (the “Company
November 14, 2023	10-Q	Note 1: Organization and Description of the Business UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36242 DMK PHARMACEUTICALS CORPORATION (Exact name of registrant as specified in its charter) Delaware 82-0429727 (State or other jurisdiction of incorporation or organization) (I.
November 14, 2023	EX-99.1	DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update Rebranded company to DMK Pharmaceuticals and appointed inaugural, passionate and committed leadership team to execute on new strategy to reduce opioid rela DMK PHARMACEUTICALS CORPORATION 8-K Exhibit 99.1 DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update Rebranded company to DMK Pharmaceuticals and appointed inaugural, passionate and committed leadership team to execute on new strategy to reduce opioid related deaths through enhanced sales of ZIMHI® and thus increase shareholder value Developed holistic co
November 14, 2023	EX-10.7	EXECUTIVE EMPLOYMENT AGREEMENT DMK Pharmaceuticals Corporation 10-Q Exhibit 10.7 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is dated as of October 23, 2023 (the “Effective Date”) and is entered into by and between DMK Pharmaceuticals Inc., a Delaware corporation (the “Company”), and John Dorbin (“Executive”). 1. Employment. The Company hereby employs Executive as General Counsel and Co
October 19, 2023	EX-10.1	EXECUTIVE EMPLOYMENT AGREEMENT DMK Pharmaceuticals Inc. 8-K Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT   THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is dated as of October 16, 2023 (the “Effective Date”) and is entered into by and between DMK Pharmaceuticals Inc., a Delaware corporation (the “Company”), and Seth A. Cohen (“Executive”). 1.            Employment. The Company hereby employs Executive as Chief Financial
October 19, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 16, 2023 DMK PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 16, 2023 DMK PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commiss
October 19, 2023	EX-10.4	DMK PHARMACEUTICALS CORPORATION INDUCEMENT STOCK OPTION AWARD AGREEMENT STOCK OPTION GRANT NOTICE __________ __, 202_ DMK Pharmaceuticals Inc. 8-K Exhibit 10.4 DMK PHARMACEUTICALS CORPORATION INDUCEMENT STOCK OPTION AWARD AGREEMENT STOCK OPTION GRANT NOTICE , 202 You (“Optionholder”, “Participant” or “Optionee”) have been granted a Nonstatutory Stock Option (the “Option” or the “option”) to purchase the number of shares of Common Stock of DMK Pharmaceuticals Corporation (the “Company”) set forth below, outside of
October 19, 2023	EX-10.2	EXECUTIVE EMPLOYMENT AGREEMENT DMK Pharmaceuticals Inc. 8-K Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is dated as of October 23, 2023 (the “Effective Date”) and is entered into by and between DMK Pharmaceuticals Inc., a Delaware corporation (the “Company”), and Seth A. Cohen (“Executive”). 1. Employment. The Company hereby employs Executive as General Counsel and Corporat
October 19, 2023	EX-10.3	DMK PHARMACEUTICALS CORPORATION INDUCEMENT STOCK OPTION AWARD AGREEMENT STOCK OPTION GRANT NOTICE October 16, 2023 DMK Pharmaceuticals Inc. 8-K Exhibit 10.3 DMK PHARMACEUTICALS CORPORATION INDUCEMENT STOCK OPTION AWARD AGREEMENT STOCK OPTION GRANT NOTICE October 16, 2023 You (“Optionholder”, “Participant” or “Optionee”) have been granted a Nonstatutory Stock Option (the “Option” or the “option”) to purchase the number of shares of Common Stock of DMK Pharmaceuticals Corporation (the “Company”) set forth below,
October 17, 2023	PX14A6G	Shareholder Jerald Hammann Discontinues DMK Pharmaceuticals Corp. Proxy Contest 240.14a-103 Notice of Exempt Solicitation (Voluntary) U.S. Securities and Exchange Commission, Washington DC 20549 Collaborative Investor Engagement Shareholder Jerald Hammann Discontinues DMK Pharmaceuticals Corp.
October 17, 2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 11, 2023 DMK PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commiss
October 12, 2023	DEFC14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. _) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
October 10, 2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 4, 2023 DMK PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commissi
October 2, 2023	PREC14A	PRELIMINARY PROXY STATEMENT SUBJECT TO COMPLETION — DATED OCTOBER 2, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 193 PRELIMINARY PROXY STATEMENT SUBJECT TO COMPLETION — DATED OCTOBER 2, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
September 26, 2023	SC 13D/A	US00547W3079 / ADAMIS PHARMACEUTICALS CORP / Versi Group LLC - AMENDMENT TO FORM SC 13D Activist Investment SC 13D/A 1 versi-sc13da091523.htm AMENDMENT TO FORM SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) DMK Pharmaceuticals Corporation (formerly named Adamis Pharmaceuticals Corporation) (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00547W307 (CUSIP Numbe
September 8, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 6, 2023 DMK PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 6, 2023 DMK PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commis
September 8, 2023	EX-99.1	Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus Company to begin trading under new ticker symbol “DMK” on September 8, 2023 DMK Pharmaceuticals Corporation 8-K Exhibit 99.1 Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus Company to begin trading under new ticker symbol “DMK” on September 8, 2023 SAN DIEGO, September 7, 2023 - Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the company changed its name to DMK Pharm
September 8, 2023	EX-3.2	Amended and Restated Bylaws of DMK Pharmaceuticals Corporation. DMK Pharmaceuticals Corporation 8-K Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF DMK PHARMACEUTICALS CORPORATION ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at su
September 8, 2023	EX-3.1	Certificate of Amendment of Restated Certificate of Incorporation of Adamis Pharmaceuticals Corporation DMK Pharmaceuticals Corporation 8-K Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF ADAMIS PHARMACEUTICALS CORPORATION Adamis Pharmaceuticals Corporation, a corporation organized under and existing under the laws of the State of Delaware (the “Company”), certifies that: FIRST: The name of the Company is Adamis Pharmaceuticals Corporation. SECOND: The Board of D
September 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 30, 2023 ADAMIS PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 30, 2023 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commi
August 29, 2023	EX-10.1	EXECUTIVE EMPLOYMENT AGREEMENT Adamis Pharmaceuticals Corporation 8-K Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is dated as of August 23, 2023 (the “Effective Date”) and is entered into by and between Adamis Pharmaceuticals Corporation, a Delaware corporation (“Company”), and Ebrahim Versi, M.D., Ph.D. (“Executive”). BACKGROUND A. In connection with the closing of the transact
August 29, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 23, 2023 ADAMIS PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 23, 2023 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commi
August 21, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36242 ADAMIS PHARMACEUTICALS CORPORATION (Exact name of registrant as specified in its charter) Delaware 82-0429727 (State or other jurisdiction of incorporation or organization) (I.
August 21, 2023	EX-99.1	Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update Adamis Pharmaceuticals Corporation 8-K Exhibit 99.1 Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update SAN DIEGO, August 21, 2023 – Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate de
August 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 21, 2023 ADAMIS PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 21, 2023 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commi
August 14, 2023	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SEC FILE NUMBER 000-26372 FORM 12b –25 NOTIFICATION OF LATE FILING CUSIP NUMBER 00547W208 Check One: ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transiti
August 10, 2023	EX-1	Exhibit 1 EX-1 2 ea183211ex99-1adamis.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreemen
August 10, 2023	SC 13G	US00547W3079 / ADAMIS PHARMACEUTICALS CORP / INTRACOASTAL CAPITAL, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Adamis Pharmaceuticals Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00547W307 (CUSIP Number) August 1, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig
August 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 1, 2023 ADAMIS PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 1, 2023 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commis
August 3, 2023	EX-99.1	Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering Adamis Pharmaceuticals Corporation 8-K Exhibit 99.1 Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering SAN DIEGO, CA – August 2, 2023 – Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”), a commercial stage biopharmaceutical company, today announced the pricing of its public offering of 5,930,000 units at a public offering price of $1.35 per unit. E
August 3, 2023	EX-10.1	SECURITIES PURCHASE AGREEMENT Adamis Pharmaceuticals Corporation 8-K Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 1, 2023, and is between Adamis Pharmaceuticals Corporation, a corporation incorporated under the laws of the state of Delaware (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and as
August 3, 2023	424B4	PROSPECTUS 5,930,000 Units consisting of 4,800,000 Shares of Common Stock and 1,130,000 Pre-Funded Warrants to purchase 1,130,000 Shares of Common Stock and 5,930,000 Warrants to purchase up to 5,930,000 Shares of Common Stock 1,130,000 Shares of Com Filed pursuant to Rule 424(b)(4) Registration No. 333-273233 PROSPECTUS 5,930,000 Units consisting of 4,800,000 Shares of Common Stock and 1,130,000 Pre-Funded Warrants to purchase 1,130,000 Shares of Common Stock and 5,930,000 Warrants to purchase up to 5,930,000 Shares of Common Stock 1,130,000 Shares of Common Stock Underlying the Pre-Funded Warrants 5,930,000 Shares of Common Stock Underlying
August 3, 2023	EX-1.1	[The remainder of this page has been intentionally left blank.] Adamis Pharmaceuticals Corporation 8-K Exhibit 1.1 August 1, 2023 Adamis Pharmaceuticals Corporation 11682 El Camino Real, Suite 300 San Diego, CA 92130 Attn: David J. Marguglio President and Chief Operating Officer This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (the “Placement Agent”) and Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”),
July 31, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 25, 2023 ADAMIS PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 25, 2023 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commiss
July 28, 2023	CORRESP	July 28, 2023 July 28, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Adamis Pharmaceuticals Corporation Registration Statement on Form S-1 File No. 333-273233 Request for Acceleration of Effective Date Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as placement
July 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 28, 2023 ADAMIS PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 28, 2023 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commiss
July 28, 2023	S-1/A	As filed with the Securities and Exchange Commission on July 28, 2023 As filed with the Securities and Exchange Commission on July 28, 2023 Registration No.
July 28, 2023	CORRESP	Adamis Pharmaceuticals Corporation 11683 El Camino Real, Suite 300 San Diego, CA 92103 July 28, 2023 Adamis Pharmaceuticals Corporation 11683 El Camino Real, Suite 300 San Diego, CA 92103 July 28, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
July 28, 2023	CORRESP	Adamis Pharmaceuticals Corporation 11683 El Camino Real, Suite 300 San Diego, CA 92103 July 28, 2023 Adamis Pharmaceuticals Corporation 11683 El Camino Real, Suite 300 San Diego, CA 92103 July 28, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
July 28, 2023	CORRESP	July 28, 2023 July 28, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Adamis Pharmaceuticals Corporation Registration Statement on Form S-1 File No. 333-273233 Request for Acceleration of Effective Date Ladies and Gentlemen: Reference is made to our letter, filed as correspondence via EDGAR on July 26, 2023, in which we, as pl
July 28, 2023	EX-99.1	Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert Adamis Pharmaceuticals Corp. 8-K Exhibit 99.1 Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert SAN DIEGO, July 28, 2023 - Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the Company has committed to fund an unrestricted research grant to the Leiden University Medical Center (LUMC) Anesthesi
July 27, 2023	EX-21.1	SUBSIDIARIES OF ADAMIS PHARMACEUTICALS CORPORATION Adamis Pharmaceuticals Corporation S-1/A Exhibit 21.1 SUBSIDIARIES OF ADAMIS PHARMACEUTICALS CORPORATION Name State of Incorporation US Compounding, Inc. Arkansas Biosyn, Inc. Pennsylvania Adamis Corporation Delaware Rhombus Pharmaceuticals Corporation Arkansas DMK Pharmaceuticals Corporation Delaware
July 27, 2023	FWP	Adamis Pharmaceuticals Corporation A biotech company focused on treating millions of patients struggling with addiction and pain July 2023 Filed Pursuant to Rule 433 Free Writing Prospectus dated July 26, 2023 Relating to Preliminary Prospectus dated Adamis Pharmaceuticals Corporation A biotech company focused on treating millions of patients struggling with addiction and pain July 2023 Filed Pursuant to Rule 433 Free Writing Prospectus dated July 26, 2023 Relating to Preliminary Prospectus dated July 26, 2023 Registration No.
July 27, 2023	S-1/A	As filed with the Securities and Exchange Commission on July 26, 2023 As filed with the Securities and Exchange Commission on July 26, 2023 Registration No.
July 26, 2023	CORRESP	Adamis Pharmaceuticals Corporation 11683 El Camino Real, Suite 300 San Diego, CA 92103 July 26, 2023 Adamis Pharmaceuticals Corporation 11683 El Camino Real, Suite 300 San Diego, CA 92103 July 26, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
July 26, 2023	CORRESP	July 26, 2023 July 26, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Adamis Pharmaceuticals Corporation Registration Statement on Form S-1 File No. 333-273233 Request for Acceleration of Effective Date Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as placement
July 24, 2023	EX-10.2	(Incorporated by reference to exhibit 10.2 to the Company’s Current Report on Form 8-K filed July 24, 2023) Adamis Pharmaceuticals Corporation 8-K Exhibit 10.2 SALES AGREEMENT FOR 1270 DON'S LN CONWAY AR ASSETS & ADAMIS/US COMPOUNDING IP 1. Definitions: For the purpose of this Agreement, the SELLER shall mean 'Operating Company'; the BUYER shall mean the company or person that is purchasing the item from the Seller. SALES REPRESENTATIVE shall mean the authorized asset broker representing the Seiler. ART
July 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 18, 2023 ADAMIS PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 18, 2023 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commiss
July 24, 2023	EX-10.1	(Incorporated by reference to exhibit 10.1 to the Company’s Current Report on Form 8-K filed July 24, 2023) Adamis Pharmaceuticals Corporation 8-K Exhibit 10.1 Certain confidential information contained in this document, marked by [***], has been omitted because it is not material and would likely cause competitive harm IF PUBLICLY DISCLOSED PURCHASE AND SALE AGREEMENT (1270 Dons Lane, Conway, Arkansas) This Purchase and Sale Agreement (this "Agreement") is entered into as of the Effective Date (defined
July 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 19, 2023 ADAMIS PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 19, 2023 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commiss
July 13, 2023	EX-4.15	SECURITIES PURCHASE AGREEMENT Adamis Pharmaceuticals Corporation S-1 Exhibit 4.15 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [], 2023, and is between Adamis Pharmaceuticals Corporation, a corporation incorporated under the laws of the state of Delaware (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns,
July 13, 2023	EX-4.12	COMMON STOCK PURCHASE WARRANT ADAMIS PHARMACEUTICALS CORPORATION Adamis Pharmaceuticals Corporation S-1 Exhibit 4.12 COMMON STOCK PURCHASE WARRANT ADAMIS PHARMACEUTICALS CORPORATION Warrant Shares: Issue Date: , 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
July 13, 2023	EX-4.13	PRE-FUNDED COMMON STOCK PURCHASE WARRANT ADAMIS PHARMACEUTICALS CORPORATION Adamis Pharmaceuticals Corporation S-1 Exhibit 4.13 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ADAMIS PHARMACEUTICALS CORPORATION Warrant Shares: Initial Exercise Date: July , 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions her
July 13, 2023	EX-FILING FEES	Calculation of Filing Fee Table (Form Type) ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in its Charter) Adamis Pharmaceuticals Corporation S-1 Exhibit 107 Calculation of Filing Fee Table S-1 (Form Type) ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Unit (1) Maximum Aggregate Offering Price (1)(2) Fee Rate Amount of Registration Fee(3) Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Equity Units, consisting of 457 (g) — — — — Equity common stock, $0.
July 13, 2023	EX-1.1	[The remainder of this page has been intentionally left blank.] Adamis Pharmaceuticals Corporation S-1 Exhibit 1.1 [], 2023 Adamis Pharmaceuticals Corporation 11682 El Camino Real, Suite 300 San Diego, CA 92130 Attn: David J. Marguglio President and Chief Operating Officer This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (the “Placement Agent”) and Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”), that t
July 13, 2023	EX-4.14	ADAMIS PHARMACEUTICALS CORPORATION EQUINITI TRUST COMPANY, LLC, as Warrant Agent Warrant Agency Agreement Dated as of July __, 2023 WARRANT AGENCY AGREEMENT Adamis Pharmaceuticals Corporation S-1 Exhibit 4.14 ADAMIS PHARMACEUTICALS CORPORATION and EQUINITI TRUST COMPANY, LLC, as Warrant Agent Warrant Agency Agreement Dated as of July , 2023 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of July , 2023 (“Agreement”), between Adamis Pharmaceuticals Corporation, a corporation organized under the laws of the State of Delaware (the “Company”),
July 13, 2023	S-1	As filed with the Securities and Exchange Commission on July 13, 2023 As filed with the Securities and Exchange Commission on July 13, 2023 Registration No.
June 16, 2023	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 24, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 24, 2023 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of inco
June 16, 2023	EX-99.3	UNAUDITED PRO FORMA CONDENSED COMBINED CONSOLIDATED BALANCE SHEETS As of March 31, 2023 ADAMIS PHARMACEUTICALS CORPORATION 8-K/A Exhibit 99.3 Unaudited Pro Forma Condensed Combined Consolidated Financial Information Adamis Pharmaceuticals Corporation (“Adamis” or the “Company”) has determined the merger transaction with DMK Pharmaceuticals Corporation (“DMK”) meets the definition of an acquisition of a business as defined in Rule 11-01(d) of Regulation S-X of the Securities Exchange
June 16, 2023	EX-99.2	DMK PHARMACEUTICALS CORPORATION COMBINED BALANCE SHEETS ADAMIS PHARMACEUTICALS CORPORATION 8-K/A Exhibit 99.2 DMK PHARMACEUTICALS CORPORATION COMBINED BALANCE SHEETS March 31, 2023 December 31, 2022 Assets Current assets: Cash $ 148,296 $ 131,310 Total current assets 148,296 131,310 Total assets $ 148,296 $ 131,310 Liabilities and stockholders' (deficit) equity Current liabilities: Accounts payable $ 4,871 $ 5,560 Due to related party 6,041 4,621 Accru
June 16, 2023	EX-99.1	Report of Independent Registered Public Accounting Firm ADAMIS PHARMACEUTICALS CORPORATION 8-K/A Exhibit 99.1 Report of Independent Registered Public Accounting Firm To the shareholders and the board of directors of DMK Pharmaceuticals Corporation Opinion on the Financial Statements We have audited the accompanying balance sheets of DMK Pharmaceuticals Corporation as of December 31, 2022 and 2021, the related statements of operations, stockholders’ equ
June 5, 2023	SC 13D	ADMP / Adamis Pharmaceuticals Corp / Versi Group LLC - ACQUISITION OF BENEFICIAL OWNERSHIP Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Adamis Pharmaceuticals Corporation (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00547W208 (CUSIP Number) Ebrahim Versi 11682 El Camino Real Suite 300 San Diego, CA 92130 Telephone: 908-698-2390 (Name, Address and Telephone Numbe
June 5, 2023	EX-1	JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13D, dated May 25, 2023, with respect to the Common Stock, par value $0.
May 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 24, 2023 ADAMIS PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 24, 2023 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commissi
May 26, 2023	EX-10.2	* * * Adamis Pharmaceuticals Corporation 8-K Exhibit 10.2 VIA ELECTRONIC MAIL Date: May 23, 2023 To: Ebrahim Versi, MD, PhD Re: Offer of Employment Adamis Pharmaceuticals Corporation Dear Eboo: Adamis Pharmaceuticals Corporation ("Company") is pleased to extend to you this conditional offer of employment to work in the full-time, officer position of Chief Executive Officer. Your primary duties and respo
May 26, 2023	EX-3.1	ADAMIS PHARMACEUTICALS CORPORATION CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES E CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW Adamis Pharmaceuticals Corporation 8-K Exhibit 3.1 ADAMIS PHARMACEUTICALS CORPORATION CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES E CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, David J. Marguglio, does hereby certify that: 1. David J. Marguglio is the Chief Executive Officer of Adamis Pharmaceuticals Co
May 26, 2023	EX-10.1	May 24, 2023 Adamis Pharmaceuticals Corporation 8-K Exhibit 10.1 May 24, 2023 David J. Marguglio Adamis Pharmaceuticals Corporation 11682 El Camino Real, Suite 300 San Diego, CA 92130 Re: Employment Agreement Dear David: This letter agreement (the “Letter”) will confirm the agreement of Adamis Pharmaceuticals Corporation (the “Company”) and you (“you,” “Executive” or “Officer”) concerning certain matters relat
May 26, 2023	EX-99.1	Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals Adamis Pharmaceuticals Corporation 8-K Exhibit 99.1 Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals ● DMK CEO, Ebrahim (Eboo) Versi, MD, PhD, named CEO and Chairman of the combined company ● Combined company will have commercial products and a library of development candidates, including two clinical stage programs ● DPI-125, the lead development program, is a clini
May 26, 2023	EX-10.3	DMK PHARMACEUTICALS, INC. 2016 STOCK PLAN Adamis Pharmaceuticals Corporation 8-K Exhibit 10.3 DMK PHARMACEUTICALS, INC. 2016 STOCK PLAN 1. Purpose. This DMK Pharmaceuticals, Inc. 2016 Stock Plan (the “Plan”) is intended to provide incentives: (a) to employees of DMK Pharmaceuticals, Inc. (the “Company”), its parent (if any), or any of its present or future subsidiaries (collectively, “Related Corporations”), by providing them with opportu
May 22, 2023	EX-3.1	Certificate of Amendment to the Restated Certificate of Incorporation of Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation 8-K Exhibit 3.1 Certificate of Amendment to the Restated Certificate of Incorporation of Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation, a corporation organized under and existing under the laws of the State of Delaware (the “Company”), certifies that: FIRST: The name of the Company is Adamis Pharmaceuticals Corporation. SECOND: The Board o
May 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 22, 2023 ADAMIS PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 22, 2023 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commissi
May 22, 2023	EX-99.1	Adamis Pharmaceuticals Announces Reverse Stock Split Adamis Pharmaceuticals Corporation 8-K Exhibit 99.1 Adamis Pharmaceuticals Announces Reverse Stock Split SAN DIEGO, May 19, 2023 – Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, announced today that it will effect a 1-for-70 reverse stock split of its common stock that will become effective on May 22, 2023, at 12:01 a.m., Eastern Time. Adamis’ comm
May 16, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2023 ADAMIS PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2023 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commissi
May 15, 2023	EX-99.1	Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update Management to host webcast/conference call today at 2:00 p.m. PT / 5:00 p.m. ET ADAMIS PHARMACEUTICALS CORPORATION 8-K Exhibit 99.1 Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update Management to host webcast/conference call today at 2:00 p.m. PT / 5:00 p.m. ET SAN DIEGO, May 15, 2023 – Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company focused on developing and commercializing produc
May 15, 2023	EX-4.2	Adamis Pharmaceuticals Corporation Prefunded Warrant TO Purchase Common Stock ADAMIS PHARMACEUTICALS CORPORATION 10-Q Exhibit 4.2 THE NUMBER OF SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO SECTION 1(a) OF THIS WARRANT. Adamis Pharmaceuticals Corporation Prefunded Warrant TO Purchase Common Stock Warrant No.: 1 Date of Issuance: March 16, 2023 (“Issuance Date”) Adamis Pharmaceuticals Corpo
May 15, 2023	EX-10.2	SUPPORT AGREEMENT ADAMIS PHARMACEUTICALS CORPORATION 10-Q Exhibit 10.2 SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this “Support Agreement”) is made and entered into as of February 24, 2023, by and between (i) each of the undersigned identified on the signature page hereof as a “Securityholder” (each, a “Securityholder”); (ii) DMK Pharmaceuticals Corporation, a New Jersey corporation (“DMK”); (iii) Adamis Pharmaceuti
May 15, 2023	EX-10.1	SECURITIES PURCHASE AGREEMENT EX-10.1 4 ex10-1.htm SECURITIES PURCHASE AGREEMENT ADAMIS PHARMACEUTICALS CORPORATION 10-Q Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 14, 2023, between Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”), and the purchaser identified on the signature pages hereto (including its successors and assigns,
May 15, 2023	10-Q	Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36242 ADAMIS PHARMACEUTICALS CORPORATION (Exact name of registrant as specified in its charter) Delaware 82-0429727 (State or other jurisdiction of incorporation or organization) (I.
May 15, 2023	EX-10.3	INDEMNITY AGREEMENT ADAMIS PHARMACEUTICALS CORPORATION 10-Q Exhibit 10.3 INDEMNITY AGREEMENT This Indemnity Agreement (the “Agreement”) is dated as of , 202, and is entered into by and between ADAMIS PHARMACEUTICALS CORPORATION, a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS A. The Company desires to attract and retain the services of highly qualified individuals as directors, officers, employee
May 15, 2023	EX-4.1	Adamis Pharmaceuticals Corporation Warrant to Purchase Common Stock ADAMIS PHARMACEUTICALS CORPORATION 10-Q Exhibit 4.1 THE NUMBER OF SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO SECTION 1(a) OF THIS WARRANT. Adamis Pharmaceuticals Corporation Warrant to Purchase Common Stock Warrant No.: 1 Date of Issuance: March 16, 2023 (“Issuance Date”) Adamis Pharmaceuticals Corporation, a
May 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2023 ADAMIS PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2023 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commissi
May 5, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2023 ADAMIS PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2023 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commissio
May 5, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commi
May 1, 2023	10-K/A	Amendment No. 1 to Annual Report on Form 10-K/A admp-10ka123122.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark one) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Fiscal Year Ended December 31, 2022 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 000-26372 ADAMIS PHAR
April 27, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commi
April 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 12, 2023 ADAMIS PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 12, 2023 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commis
April 13, 2023	DEFM14A	Definitive Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
April 13, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commi
March 31, 2023	PREM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. _) PREM14A 1 admp-prem14a032423.htm PRELIMINARY PROXY STATEMENTS RELATING TO MERGER OR ACQUISITION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Sta
March 31, 2023	EX-FILING FEES	Calculation of Filing Fee Tables Schedule 14A ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Exhibit 107 Calculation of Filing Fee Tables Schedule 14A ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Proposed Maximum Aggregate Value of Transaction Fee Rate Amount of Filing Fee Fees to Be Paid $27,000,000 0.
March 17, 2023	EX-99.3	Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET ADAMIS PHARMACEUTICALS CORPORATION 8-K Exhibit 99.3 Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET SAN DIEGO, March 16, 2023 – Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company focused on developing and commercializing products in various therapeutic
March 17, 2023	EX-99.3	Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET ADAMIS PHARMACEUTICALS CORPORATION 8-K Exhibit 99.3 Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET SAN DIEGO, March 16, 2023 – Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company focused on developing and commercializing products in various therapeutic
March 17, 2023	EX-99.1	*** Q&A SESSION *** ADAMIS PHARMACEUTICALS CORPORATION 8-K Exhibit 99.1 Conference Call Transcript Adamis Pharmaceuticals Corporation 2022 Financial Results and Corporate Update Conference Call and Webcast March 16, 2023, 5:00 p.m. ET Corporate Officers and Speakers David Marguglio, CEO, Adamis David Benedicto, CFO, Adamis Eboo Versi, M.D., DMK Pharmaceuticals Corporation [OPERATOR] Good afternoon ladies and gentleme
March 17, 2023	EX-99.1	*** Q&A SESSION *** EX-99.1 2 ex99-1.htm TRANSCRIPT OF CONFERENCE CALL ADAMIS PHARMACEUTICALS CORPORATION 8-K Exhibit 99.1 Conference Call Transcript Adamis Pharmaceuticals Corporation 2022 Financial Results and Corporate Update Conference Call and Webcast March 16, 2023, 5:00 p.m. ET Corporate Officers and Speakers David Marguglio, CEO, Adamis David Benedicto, CFO, Adamis Eboo Versi, M.D., DMK Pharmaceuticals Corpor
March 17, 2023	EX-99.2	Transcript of Video Presentation ADAMIS PHARMACEUTICALS CORPORATION 8-K Exhibit 99.2 Transcript of Video Presentation Narrator: Welcome to our discussion about the proposed merger transaction between Adamis Pharmaceuticals and DMK Pharmaceuticals. Today Adamis announced that they had entered into an agreement and plan of merger with DMK Pharmaceuticals. I’m here with the CEOs of both organizations to learn more as they share with
March 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2023 ADAMIS PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2023 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commis
March 17, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2023 ADAMIS PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2023 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commis
March 17, 2023	EX-99.2	Transcript of Video Presentation ADAMIS PHARMACEUTICALS CORPORATION 8-K Exhibit 99.2 Transcript of Video Presentation Narrator: Welcome to our discussion about the proposed merger transaction between Adamis Pharmaceuticals and DMK Pharmaceuticals. Today Adamis announced that they had entered into an agreement and plan of merger with DMK Pharmaceuticals. I’m here with the CEOs of both organizations to learn more as they share with
March 16, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2023 ADAMIS PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2023 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commis
March 16, 2023	10-K	Annual Report on Form 10-K for the year ended December 31, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2022 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 000-26372 ADAMIS PHARMACEUTICALS CORPORATION (Exact name of
March 16, 2023	EX-99.1	Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET ADAMIS PHARMACEUTICALS CORPORATION 8-K Exhibit 99.1 Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET SAN DIEGO, March 16, 2023 – Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company focused on developing and commercializing products in various therapeutic
March 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 14, 2023 ADAMIS PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 14, 2023 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commis
March 14, 2023	EX-99.1	Adamis Pharmaceuticals Announces $3.0 Million Registered Direct Offering Adamis Pharmaceuticals Corporation 8-K Exhibit 99.1 Adamis Pharmaceuticals Announces $3.0 Million Registered Direct Offering SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) - Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respira
March 14, 2023	EX-4.1	FORM OF WARRANT Adamis Pharmaceuticals Corporation 8-K Exhibit 4.1 FORM OF WARRANT THE NUMBER OF SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO SECTION 1(a) OF THIS WARRANT. Adamis Pharmaceuticals Corporation Warrant To Purchase Common Stock Warrant No.: Date of Issuance: March [ ], 2023 (“Issuance Date”) Adamis Pharmaceuticals C
March 14, 2023	EX-4.2	FORM OF PREFUNDED WARRANT Adamis Pharmaceuticals Corporation 8-K Exhibit 4.2 FORM OF PREFUNDED WARRANT THE NUMBER OF SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO SECTION 1(a) OF THIS WARRANT. Adamis Pharmaceuticals Corporation Prefunded Warrant To Purchase Common Stock Warrant No.: Date of Issuance: March [ ], 2023 (“Issuance Date”) Adam
March 14, 2023	424B5	16,500,000 Shares of Common Stock Warrants to purchase 48,000,000 Shares of Common Stock Prefunded Warrants to purchase 7,500,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-267365 PROSPECTUS SUPPLEMENT (To Prospectus dated September 19, 2022) 16,500,000 Shares of Common Stock Warrants to purchase 48,000,000 Shares of Common Stock Prefunded Warrants to purchase 7,500,000 Shares of Common Stock We are offering (i) 16,500,000 shares of common stock (the “Common Shares”), (ii) warrants to purchase an aggregate of 48,0
March 14, 2023	EX-10.1	SECURITIES PURCHASE AGREEMENT Adamis Pharmaceuticals Corporation 8-K Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 14, 2023, between Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”), and the purchaser identified on the signature pages hereto (including its successors and assigns, the “Purchaser”). WHEREAS, subject to the terms and
February 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 24, 2023 ADAMIS PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 24, 2023 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Com
February 27, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 24, 2023 ADAMIS PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 24, 2023 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Com
February 27, 2023	EX-10.1	SUPPORT AGREEMENT ADMP 8-K Exhibit 10.1 SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this “Support Agreement”) is made and entered into as of February 24, 2023, by and between (i) each of the undersigned identified on the signature page hereof as a “Securityholder” (each, a “Securityholder”); (ii) DMK Pharmaceuticals Corporation, a New Jersey corporation (“DMK”); (iii) Adamis Pharmaceuticals Corporation, a Delaware co
February 27, 2023	EX-2.1	AGREEMENT AND PLAN OF MERGER AND REORGANIZATION ADAMIS PHARMACEUTICALS CORPORATION, a Delaware corporation, AARDVARK MERGER SUB, INC., a Delaware corporation DMK PHARMACEUTICALS CORPORATION, a New Jersey corporation Dated as of February 24, 2023 TABL ADMP 8-K Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION between ADAMIS PHARMACEUTICALS CORPORATION, a Delaware corporation, AARDVARK MERGER SUB, INC., a Delaware corporation and DMK PHARMACEUTICALS CORPORATION, a New Jersey corporation Dated as of February 24, 2023 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 1.1 Merger of DMK into Merger Sub 2 1.2 Effect of the Merger 2 1.3 Closing;
February 27, 2023	EX-99.1	Adamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of Merger ADMP 8-K Exhibit 99.1 Adamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of Merger • Combined company will have commercial products and a library of development candidates, two of which are clinical stage • Will be under the leadership of DMK CEO, Dr. Ebrahim (Eboo) Versi MD, PhD • Lead development program will be a clinical stage therapeutic under development for the treat
February 27, 2023	EX-2.1	AGREEMENT AND PLAN OF MERGER AND REORGANIZATION ADAMIS PHARMACEUTICALS CORPORATION, a Delaware corporation, AARDVARK MERGER SUB, INC., a Delaware corporation DMK PHARMACEUTICALS CORPORATION, a New Jersey corporation Dated as of February 24, 2023 TABL ADMP 8-K Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION between ADAMIS PHARMACEUTICALS CORPORATION, a Delaware corporation, AARDVARK MERGER SUB, INC., a Delaware corporation and DMK PHARMACEUTICALS CORPORATION, a New Jersey corporation Dated as of February 24, 2023 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 1.1 Merger of DMK into Merger Sub 2 1.2 Effect of the Merger 2 1.3 Closing;
February 27, 2023	EX-10.1	SUPPORT AGREEMENT ADMP 8-K Exhibit 10.1 SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this “Support Agreement”) is made and entered into as of February 24, 2023, by and between (i) each of the undersigned identified on the signature page hereof as a “Securityholder” (each, a “Securityholder”); (ii) DMK Pharmaceuticals Corporation, a New Jersey corporation (“DMK”); (iii) Adamis Pharmaceuticals Corporation, a Delaware co
February 27, 2023	EX-99.1	Adamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of Merger ADMP 8-K Exhibit 99.1 Adamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of Merger • Combined company will have commercial products and a library of development candidates, two of which are clinical stage • Will be under the leadership of DMK CEO, Dr. Ebrahim (Eboo) Versi MD, PhD • Lead development program will be a clinical stage therapeutic under development for the treat
February 23, 2023	EX-99.1	Nasdaq Grants Adamis Pharmaceuticals’ Request for Extension to Comply with Continued Listing Requirements Adamis Pharmaceuticals Corporation 8-K Exhibit 99.1 Nasdaq Grants Adamis Pharmaceuticals’ Request for Extension to Comply with Continued Listing Requirements SAN DIEGO, February 22, 2023 – Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdos
February 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 21, 2023 ADAMIS PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 21, 2023 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Com
December 30, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 28, 2022 ADAMIS PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 28, 2022 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Com
November 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36242 ADAMIS PHARMACEUTICALS CORPORATION (Exact name of registrant as specified in its charter) Delaware 82-0429727 (State or other jurisdiction of incorporation or organization) (I.
November 14, 2022	EX-99.1	Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update Management to host webcast/conference call today at 2:00 p.m. PT / 5:00 p.m. ET Adamis Pharmaceuticals Corporation 8-K Exhibit 99.1 Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update Management to host webcast/conference call today at 2:00 p.m. PT / 5:00 p.m. ET SAN DIEGO, November 14, 2022 ? Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commerc
November 14, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2022 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Com
October 4, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 1, 2022 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commi
October 4, 2022	EX-99.1	Adamis Announces Review of Strategic Alternatives Adamis Pharmaceuticals Corporation 8-K Exhibit 99.1 Adamis Announces Review of Strategic Alternatives SAN DIEGO, October 3, 2022- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, announced today
October 4, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2022 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commi
September 23, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2022 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Co
September 23, 2022	424B5	Up to 13,794,000 Shares of Common Stock Issuable Upon Exercise of Warrants PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus dated September 19, 2022) Registration No.
September 21, 2022	EX-99.1	Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects Adamis Pharmaceuticals Corporation 8-K Exhibit 99.1 Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects ? Interim data from the Phase 2/3 clinical trial of Tempol did not demonstrate statistical significance of its primary endpoint of clinical resolution of COVID-19 symptoms at day 14 versus placebo ? Independent Data Safety Monitoring Board recommends h
September 21, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2022 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Co
September 20, 2022	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 2 (Mark one) ? Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Fiscal Year Ended December 31, 2021 OR ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 000-26372 ADAMIS PHARMACEUTICALS CORPORAT
September 16, 2022	CORRESP	Adamis Pharmaceuticals Corporation 11682 El Camino Real, Suite 300 San Diego, CA 92130 Adamis Pharmaceuticals Corporation 11682 El Camino Real, Suite 300 San Diego, CA 92130 September 16, 2022 VIA EDGAR U.
September 12, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2022 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Com
September 9, 2022	EX-4.3	ADAMIS PHARMACEUTICALS CORPORATION Dated as of ___________, 20___ TABLE OF CONTENTS Adamis Pharmaceuticals Corporation S-3 Exhibit 4.3 ADAMIS PHARMACEUTICALS CORPORATION INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Sectio
September 9, 2022	EX-FILING FEES	Calculation of Filing Fee Tables Form S-3 (Form Type) Adamis Pharmaceuticals Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities EX-FILING FEES 6 ex107.htm FEE TABLE Adamis Pharmaceuticals Corporation S-3 Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Adamis Pharmaceuticals Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offer
September 9, 2022	S-3	Subject to Completion, dated September 9, 2022 As filed with the Securities and Exchange Commission on September 9, 2022 S-3 1 admp-s3090922.htm REGISTRATION STATEMENT The information in this prospectus is not complete and may be changed. We may not sell these securities until the Registration Statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state where the offer or sale is
August 18, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commi
August 17, 2022	8-K	Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2022 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commi
August 17, 2022	EX-99.1	Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders Meeting adjourned only with respect to reverse stock split proposal until September 8, 2022 Adamis Pharmaceuticals Corporation 8-K Exhibit 99.1 Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders Meeting adjourned only with respect to reverse stock split proposal until September 8, 2022 SAN DIEGO, August 12, 2022- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its 2022 Annual Meeting of Stockholders (?Annual Meeting?) was convened, as schedu
August 15, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commi
August 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36242 ADAMIS PHARMACEUTICALS CORPORATION (Exact name of registrant as specified in its charter) Delaware 82-0429727 (State or other jurisdiction of incorporation or organization) (I.
August 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 10, 2022 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commi
August 10, 2022	EX-99.1	Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update Management to host webcast/conference call today at 1:30 p.m. PT / 4:30 p.m. ET ADAMIS PHARMACEUTICALS CORPORATION 8-K Exhibit 99.1 Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update Management to host webcast/conference call today at 1:30 p.m. PT / 4:30 p.m. ET SAN DIEGO, August 10, 2022 ? Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commerci
August 5, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commi
August 1, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 29, 2022 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commiss
August 1, 2022	EX-99.1	Interim DSMB review expected in late September Adamis Pharmaceuticals Corporation 8-K Exhibit 99.1 Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19 Interim DSMB review expected in late September SAN DIEGO, July 29, 2022 (GLOBE NEWSWIRE) - Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the Company?s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety
July 29, 2022	EX-99.1	Leading Independent Proxy Advisory Firm ISS Recommends Adamis Pharmaceuticals’ Stockholders Vote FOR Critical Proposals at Upcoming Annual Meeting ISS Recommends Stockholders Support Key Proposals Pertaining to a Reverse Stock Split and New Equity In Adamis Pharmaceuticals Corporation 8-K Exhibit 99.1 Leading Independent Proxy Advisory Firm ISS Recommends Adamis Pharmaceuticals’ Stockholders Vote FOR Critical Proposals at Upcoming Annual Meeting ISS Recommends Stockholders Support Key Proposals Pertaining to a Reverse Stock Split and New Equity Incentive Plan The Deadline for Stockholders to Vote (or Change Their Vote) is 11:59 p.m. PT on Augu
July 29, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commi
July 29, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 29, 2022 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commiss
July 21, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commi
July 7, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. _) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
July 6, 2022	EX-3.1	ADAMIS PHARMACEUTICALS CORPORATION CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW ADAMIS PHARMACEUTICALS CORPORATION 8-K EXHIBIT 3.1 ADAMIS PHARMACEUTICALS CORPORATION CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, David J. Marguglio, does hereby certify that: 1. David J. Marguglio is the President of Adamis Pharmaceuticals Corporation, a D
July 6, 2022	EX-10.1	SECURITIES PURCHASE AGREEMENT ADAMIS PHARMACEUTICALS CORPORATION DEFA14A Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of July 5, 2022, between Adamis Pharmaceuticals Corporation, a Delaware corporation (the ?Company?), the purchaser identified on the signature pages hereto (including its successors and assigns, the ?Purchaser?). WHEREAS, subject to the terms and c
July 6, 2022	EX-10.2	REGISTRATION RIGHTS AGREEMENT ADAMIS PHARMACEUTICALS CORPORATION 8-K Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of July 5, 2022, between Adamis Pharmaceuticals Corporation, a Delaware corporation (the ?Company?), and purchaser signatory hereto (the ?Purchaser?). This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the
July 6, 2022	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 30, 2022 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commiss
July 6, 2022	EX-10.1	SECURITIES PURCHASE AGREEMENT ADAMIS PHARMACEUTICALS CORPORATION 8-K Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of July 5, 2022, between Adamis Pharmaceuticals Corporation, a Delaware corporation (the ?Company?), the purchaser identified on the signature pages hereto (including its successors and assigns, the ?Purchaser?). WHEREAS, subject to the terms and condi
July 6, 2022	EX-4.1	COMMON STOCK PURCHASE WARRANT ADAMIS PHARMACEUTICALS CORPORATION ADAMIS PHARMACEUTICALS CORPORATION 8-K Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR UNDER APPLICABLE STATE SECURITIES OR BLUE
July 6, 2022	EX-3.1	ADAMIS PHARMACEUTICALS CORPORATION CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW ADAMIS PHARMACEUTICALS CORPORATION DEFA14A EXHIBIT 3.1 ADAMIS PHARMACEUTICALS CORPORATION CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, David J. Marguglio, does hereby certify that: 1. David J. Marguglio is the President of Adamis Pharmaceuticals Corporation,
July 6, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 30, 2022 ADAMIS PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 30, 2022 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commiss
July 6, 2022	EX-10.2	REGISTRATION RIGHTS AGREEMENT ADAMIS PHARMACEUTICALS CORPORATION DEFA14A Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of July 5, 2022, between Adamis Pharmaceuticals Corporation, a Delaware corporation (the ?Company?), and purchaser signatory hereto (the ?Purchaser?). This Agreement is made pursuant to the Securities Purchase Agreement, dated as of
July 6, 2022	EX-4.1	COMMON STOCK PURCHASE WARRANT ADAMIS PHARMACEUTICALS CORPORATION ADAMIS PHARMACEUTICALS CORPORATION DEFA14A Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR UNDER APPLICABLE STATE SECURITIES OR B
June 24, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 22, 2022 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commiss
June 24, 2022	EX-10.1	EXECUTIVE EMPLOYMENT AGREEMENT ADAMIS PHARMACEUTICALS CORPORATION 8-K Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (?Agreement?) is dated as of June 22, 2022 (the ?Effective Date?) and is entered into by and between Adamis Pharmaceuticals Corporation, a Delaware corporation (?Company?), and David C. Benedicto (?Executive?). RECITALS A. Executive is currently employed by the Company as its Chie
June 17, 2022	EX-3.1	Amended and Restated Bylaws of the Company. Adamis Pharmaceuticals Corporation 8-K Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF ADAMIS PHARMACEUTICALS CORPORATION ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business
June 17, 2022	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 14, 2022 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commiss
June 17, 2022	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. _) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
May 26, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 24, 2022 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commissi
May 26, 2022	EX-10.1	Adamis Appoints Vickie Reed to Board of Directors New Director Named with Significant Executive Management and Financial Leadership Experience EX-10.1 2 ex99-1.htm PRESS RELEASE Adamis Pharmaceuticals Corporation 8-K Exhibit 99.1 Adamis Appoints Vickie Reed to Board of Directors New Director Named with Significant Executive Management and Financial Leadership Experience SAN DIEGO, May 26, 2022 - Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the appointment of Vickie Reed as a new director and member of the company’s b
May 19, 2022	EX-99.1	Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth David J. Marguglio, Co-Founder and Chief Business Officer, Appointed President and CEO Dennis J. Carlo, Ph.D. Has Retired as Both CEO and Board Direc Adamis Pharmaceuticals Corporation 8-K Exhibit 99.1 Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth David J. Marguglio, Co-Founder and Chief Business Officer, Appointed President and CEO Dennis J. Carlo, Ph.D. Has Retired as Both CEO and Board Director SAN DIEGO, May 18, 2022 - Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutic
May 19, 2022	EX-10.2	Executive Employment Agreement between the Company and David J. Marguglio dated as of May 18, 2022. Adamis Pharmaceuticals Corporation 8-K Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (?Agreement?) is dated as of May 18, 2022 (the ?Effective Date?) and is entered into by and between Adamis Pharmaceuticals Corporation, a Delaware corporation (?Company?), and David J. Marguglio (?Executive?). RECITALS A. Executive is currently employed by the Company as its Senio
May 19, 2022	EX-10.1	Separation Agreement and Release dated as of May 18, 2022. Adamis Pharmaceuticals Corporation 8-K Exhibit 10.1 May 18, 2022 Dennis J. Carlo, Ph.D. P.O. Box 1176 Rancho Santa Fe, CA 92067 Re: Separation Agreement and Release Dear Dennis: This letter agreement (this ?Agreement?) sets forth the terms and conditions of your separation from employment with Adamis Pharmaceuticals Corporation (?Adamis? or the ?Company?). Your separation from employment with the
May 19, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 17, 2022 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commissi
May 16, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36242 ADAMIS PHARMACEUTICALS CORPORATION (Exact name of registrant as specified in its charter) Delaware 82-0429727 (State or other jurisdiction of incorporation or organization) (I.
May 16, 2022	EX-99.1	Adamis Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET ADAMIS PHARMACEUTICALS CORPORATION 8-K Exhibit 99.1 Adamis Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET SAN DIEGO, May 16, 2022 ? Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid o
May 16, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 16, 2022 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commissi
May 9, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 3, 2022 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commissio
May 2, 2022	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 10-K/A 1 admp-10ka123121.htm AMENDMENT TO FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark one) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Fiscal Year Ended December 31, 2021 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission F
April 11, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 7, 2022 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commiss
March 31, 2022	EX-10.22	Adamis Pharmaceuticals Corporation 10-K Adamis Pharmaceuticals Corporation 10-K Exhibit 10.22 CERTAIN MARKED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. SUCH OMITTED INFORMATION IS INDICATED BY BRACKETS (?[?***?]? IN THIS EXHIBIT. November 21, 2014 Dennis J. Carlo, Ph.D. President & CEO Personal and Confiden
March 31, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 31, 2022 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commis
March 31, 2022	EX-10.45	FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT EX-10.45 3 ex10-45.htm FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT Adamis Pharmaceuticals Corporation 10-K Exhibit 10.45 Confidential CERTAIN MARKED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. SUCH OMITTED INFORMATION IS INDICATED BY BRACKETS (“[…***…]” IN THIS EXHI
March 31, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ? Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2021 OR ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 000-26372 ADAMIS PHARMACEUTICALS CORPORATION (Exact name of
March 31, 2022	EX-99.1	Adamis Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET Adamis Pharmaceuticals Corp. 8-K Exhibit 99.1 Adamis Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET SAN DIEGO, March 31, 2022 ? Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose,
March 28, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 21, 2022 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commis
March 28, 2022	EX-99.1	Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (epinephrine) Injection for Potential Manufacturing Defect EX-99.1 2 ex99-1.htm PRESS RELEASE DATED MARCH 21, 2022 Adamis Pharmaceuticals Corporation 8-K Exhibit 99.1 Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (epinephrine) Injection for Potential Manufacturing Defect San Diego, March 21, 2022 – Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) is voluntarily recalling certain lots of SYMJEPI (epinephrine) Injection
March 3, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 25, 2022 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Com
February 18, 2022	EX-14.1	Code of Business Conduct and Ethics. Adamis Pharmaceuticals Corporation 8-K Exhibit 14.1 ADAMIS PHARMACEUTICALS CORPORATION CODE OF BUSINESS CONDUCT AND ETHICS This Code of Business Conduct and Ethics (this ?Code?) reflects the commitment of Adamis Pharmaceuticals Corporation (the ?Company?) to compliance and an ethical culture. This reflects the business practices and principles of behavior that support this commitment. The Company
February 18, 2022	8-K	Amendment to Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 15, 2022 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Com
January 10, 2022	EX-99.1	Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19 Adamis Pharmaceuticals Corporation 8-K Exhibit 99.1 Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19 SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) - Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration (FDA) for Tempol for the treatment an
January 10, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 10, 2022 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Comm
January 4, 2022	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 31, 2021 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Com
November 23, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 23, 2021 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Com
November 22, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36242 ADAMIS PHARMACEUTICALS CORPORATION (Exact name of registrant as specified in its charter) Delaware 82-0429727 (State or other jurisdiction of incorporation or organization) (I.
November 22, 2021	EX-10.1	Settlement Agreement between the Company, US Compounding Inc., Nephron Pharmaceuticals Corporation, Nephron S.C., Inc., Nephron Sterile Compounding Center, LLC and certain other parties. +* Adamis Pharmaceuticals, Corporation 10-Q Exhibit 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is both not material and is the type that the Registrant treats as private or confidential. SETTLEMENT AGREEMENT This Settlement Agreement (?Agreement?) is entered into among Nephron Pharmaceuticals Corporation, Ne
November 22, 2021	EX-99.1	Adamis Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET Adamis Pharmaceuticals Corporation 8-K Exhibit 99.1 Adamis Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET SAN DIEGO ? November 22, 2021 ? Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy,
November 22, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36242 ADAMIS PHARMACEUTICALS CORPORATION (Exact name of registrant as specified in its charter) Delaware 82-0429727 (State or other jurisdiction of incorporation or organization) (I.
November 22, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 22, 2021 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Com
November 22, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36242 ADAMIS PHARMACEUTICALS CORPORATION (Exact name of registrant as specified in its charter) Delaware 82-0429727 (State or other jurisdiction of incorporation or organization) (I.
November 15, 2021	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SEC FILE NUMBER 000-26372 FORM 12b ?25 NOTIFICATION OF LATE FILING CUSIP NUMBER 00547W208 Check One: ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR For Period Ended: September 30, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Tra
October 18, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 15, 2021 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Comm
October 18, 2021	EX-99.1	Adamis Receives FDA Approval for ZIMHI New High-Dose Naloxone Product for the Treatment of Opioid Overdose Adamis Pharmaceuticals Corporation 8-K Exhibit 99.1 Adamis Receives FDA Approval for ZIMHI New High-Dose Naloxone Product for the Treatment of Opioid Overdose SAN DIEGO, Oct. 18, 2021 (Globe Newswire) - Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has approved Adamis? ZIMHI ? (naloxone HCL Injection, USP) 5 mg/0.5 mL product. ZI
October 4, 2021	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 30, 2021 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Co
October 4, 2021	EX-10.1	10.1 Press Release dated October 4, 2021 Adamis Pharmaceuticals Corporation 8-K Exhibit 10.1 Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors Appointment of New Director with Significant Experience in Drug Development, Licensing and Commercialization SAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) - Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the appointment of Meera J. Desai, Ph.D., as a new dire
September 13, 2021	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 7, 2021 ADAMIS PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 7, 2021 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Com
August 24, 2021	EX-99.1	Adamis Announces Appointment of David C. Benedicto as Chief Financial Officer and Other Events Adamis Pharmaceuticals Corporation 8-K Exhibit 99.1 Adamis Announces Appointment of David C. Benedicto as Chief Financial Officer and Other Events SAN DIEGO, August 24, 2021 - Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that David C. Benedicto, who has been serving as the Company?s Chief Accounting Officer, will succeed Robert O. Hopkins as Chief Financial Officer, effective
August 24, 2021	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 20, 2021 ADAMIS PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 20, 2021 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commi
August 18, 2021	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 12, 2021 ADAMIS PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 12, 2021 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commi
August 16, 2021	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SEC FILE NUMBER 000-26372 FORM 12b ?25 NOTIFICATION OF LATE FILING CUSIP NUMBER 00547W208 Check One: ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR For Period Ended: June 30, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transiti
August 5, 2021	EX-2.1	Asset Purchase Agreement Adamis Pharmaceuticals Corp 8-K Exhibit 2.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is both not material and is the type that the Registrant treats as private or confidential. Asset Purchase Agreement This Asset Purchase Agreement (the ?Agreement,? which term shall include the Exhibits hereto) is hereby ent
August 5, 2021	EX-99.1	UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS OF ADAMIS PHARMACEUTICALS CORPORATION EX-99.1 4 ex99-1.htm UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Adamis Pharmaceuticals Corp 8-K Exhibit 99.1 UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS OF ADAMIS PHARMACEUTICALS CORPORATION Overview On July 30, 2021, Adamis Pharmaceuticals Corporation (the “Company”) and the Company’s wholly-owned subsidiary US Compounding, Inc. (“USC”) entered into an Asset Purchas
August 5, 2021	EX-10.1	SUPPLY AGREEMENT ADDENDUM Adamis Pharmaceuticals Corp 8-K Exhibit 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is both not material and is the type that the Registrant treats as private or confidential. SUPPLY AGREEMENT ADDENDUM This Supply Agreement Addendum (the ?Addendum?), is entered into by and between Fagron Compounding Servic
August 5, 2021	EX-99.2	Adamis Announces Agreement to Sell Portion of US Compounding Business Transaction Proceeds Will be Used for General Corporate Purposes and Funding Intended Acceleration of Pharmaceutical Pipeline Adamis Pharmaceuticals Corp 8-K Exhibit 99.2 Adamis Announces Agreement to Sell Portion of US Compounding Business Transaction Proceeds Will be Used for General Corporate Purposes and Funding Intended Acceleration of Pharmaceutical Pipeline SAN DIEGO, August 4, 2021- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (?Adamis? or the ?Company?) today announced that it has entered into a definitive
August 5, 2021	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Material Impairments, Costs Associated with Exit or Disposal Activities, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 30, 2021 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commiss
July 19, 2021	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 16, 2021 ADAMIS PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 16, 2021 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commiss
July 13, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commi
July 13, 2021	EX-99.1	Adamis Pharmaceuticals Corporation 8-K Adamis Pharmaceuticals Corporation 8-K Exhibit 99.1 Investor Presentation July 2021 2 3 Adamis is focused on developing treatments for patients facing two of the world?s most harrowing health challenges: SARS - CoV - 2 and opioid overdose By advancing our high - potential product pipeline, we seek to d eliver enduring value for our stockholders and society as a whole 4 Tempol Advance Tempol, a nov
July 13, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commi
July 13, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 12, 2021 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commiss
July 1, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commi
June 28, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commi
June 23, 2021	PREC14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Ame PREC14A 1 prec14aHammann20200623.htm 2021 HAMMANN PRELIMINARY PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the R
June 14, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commi
June 14, 2021	DEFC14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide
June 2, 2021	DFAN14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Ame DFAN14A 1 blog20210602.htm BLOG POST DATED JUNE 2, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the
June 1, 2021	EX-99.1	Adamis Pharmaceuticals Announces Receipt of Deficiency Letter from Nasdaq Adamis Pharmaceuticals Corporation 8-K Exhibit 99.1 Adamis Pharmaceuticals Announces Receipt of Deficiency Letter from Nasdaq SAN DIEGO ? May 28, 2021 ? Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose (the ?Company?), today announced that, as expected, on May 25, 20
June 1, 2021	PREC14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide
June 1, 2021	8-K	Regulation FD Disclosure, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 25, 2021 ADAMIS PHARMACEUTICALS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26372 82-0429727 (State or other jurisdiction of incorporation) (Commissi

DMKPQ / DMK Pharmaceuticals Corporation - Документы SEC, Годовой отчет, Доверенное заявление

Основная статистика

SEC Filings

SEC Filings (Chronological Order)

Other Listings